Fennec Pharmaceuticals Inc
Ownership
Ownership Structure
Who owns Fennec Pharmaceuticals Inc (FENC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 56.7% of the shares are freely tradable; institutional investors hold 54.3%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 8.29 | 2,908,201 | +11.3 | 03/31/2026 |
| AIGH Capital Management, LLC | 7.09 | 2,486,038 | +25.5 | 06/30/2026 |
| Solas Capital Management LLC | 7.08 | 2,482,198 | -3.1 | 03/31/2026 |
| BlackRock Inc | 3.90 | 1,368,176 | +10.8 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.56 | 897,144 | +0.0 | 03/31/2026 |
| Awm Investment Company Inc | 2.05 | 720,135 | +1.2 | 03/31/2026 |
| Prospect Capital Advisors, LLC | 1.42 | 497,800 | +0.0 | 06/30/2026 |
| Geode Capital Management, LLC | 1.06 | 371,738 | +25.1 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.32 | 815,192 | +0.0 | 07/31/2026 |
| iShares Russell 2000 ETF | 2.12 | 742,194 | -0.6 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Andrade Robert | CHIEF FINANCIAL OFFICER | 241,306 | 2,606,105 $ | Aug 31, 2026 | direct |
| Raykov Rosty | Former Director | 124,411 | 1,343,639 $ | Sep 1, 2026 | direct |
| Hackman Jeffrey S. | Chief Executive Officer | 66,302 | 716,062 $ | Aug 31, 2026 | direct |
| Cioffi Christiana Marie | Chief Strategy Officer | 24,644 | 266,155 $ | Aug 31, 2026 | direct |
| Evans Terry L | Chief Commercial Officer | 21,519 | 232,405 $ | Aug 31, 2026 | direct |
| Sayad Pierre Sargis | Chief Medical Officer | 9,519 | 102,805 $ | Aug 31, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Brughera Marco Maria | Director | Sell | 15,545 | 10.29 | 159,958 |
| Sep 15, 2026 | Brughera Marco Maria | Director | Other | 15,545 | 2.11 | 32,800 |
| Sep 1, 2026 | Raykov Rosty | Former Director | Sell | 10,000 | 12.11 | 121,100 |
| Aug 31, 2026 | Raykov Rosty | Former Director | Other | 2,778 | 0.00 | – |
| Aug 31, 2026 | Cioffi Christiana Marie | Chief Strategy Officer | Other | 156 | 0.00 | – |
| Aug 31, 2026 | Sayad Pierre Sargis | Chief Medical Officer | Sell | 12,000 | 12.18 | 146,160 |
| Aug 31, 2026 | Sayad Pierre Sargis | Chief Medical Officer | Other | 168 | 0.00 | – |
| Aug 31, 2026 | Evans Terry L | Chief Commercial Officer | Other | 168 | 0.00 | – |
| Aug 31, 2026 | Hackman Jeffrey S. | Chief Executive Officer | Other | 1,159 | 0.00 | – |
| Aug 31, 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | Other | 1,703 | 0.00 | – |
| Aug 28, 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | Other | 21,928 | 5.10 | 111,833 |
| Aug 27, 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | Sell | 75,000 | 11.78 | 883,500 |
| Aug 3, 2026 | Raykov Rosty | Former Director | Sell | 10,000 | 9.58 | 95,800 |
| Jul 31, 2026 | Cioffi Christiana Marie | Chief Strategy Officer | Other | 156 | 0.00 | – |
| Jul 31, 2026 | Sayad Pierre Sargis | Chief Medical Officer | Other | 168 | 0.00 | – |
| Jul 31, 2026 | Evans Terry L | Chief Commercial Officer | Other | 168 | 0.00 | – |
| Jul 31, 2026 | Hackman Jeffrey S. | Chief Executive Officer | Other | 1,159 | 0.00 | – |
| Jul 31, 2026 | Raykov Rosty | Former Director | Other | 2,778 | 0.00 | – |
| Jul 31, 2026 | Andrade Robert | CHIEF FINANCIAL OFFICER | Other | 1,703 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.